Q-omics provides the consensus-scored NUDT3 profile across patient tissues and cancer cell-line models. NUDT3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, NUDT3 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, NUDT3 RNA expression shows 20,289 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, and UVM as cancer lineages where NUDT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT3 survival associations across molecular data types. NUDT3 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT3 RNA expression–survival associations across cancer types. High NUDT3 expression shows unfavorable associations in COAD, ACC, LIHC and KICH, but favorable associations in KIRC and READ. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for NUDT3 RNA expression.
This table summarizes NUDT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NUDT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT3 shows higher tumor expression in COAD, LIHC, STAD, LUAD, HNSC and LUSC. The COAD box plot shows higher NUDT3 RNA expression in tumor versus normal tissue (log2 FC = +0.525, t-test p < 0.001).
This table shows molecular features associated with NUDT3 in patient tissues and cancer cell lines. In patient samples, NUDT3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUDT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
